Cas:10564-55-3 1-(isocyanatomethylsulfonyl)-4-methylbenzene manufacturer & supplier

We serve Chemical Name:1-(isocyanatomethylsulfonyl)-4-methylbenzene CAS:10564-55-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-(isocyanatomethylsulfonyl)-4-methylbenzene

Chemical Name:1-(isocyanatomethylsulfonyl)-4-methylbenzene
CAS.NO:10564-55-3
Synonyms:p-tolylsulfonylmethyl isocyanide;tosylmethylisocyanate;toluene-4-sulfonylmethylisocyanide;p-toluenesulfonylmethyl isocyanate
Molecular Formula:C9H9NO3S
Molecular Weight:211.23800
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:71.95000
Exact Mass:211.03000
LogP:2.14280

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like p-tolylsulfonylmethyl isocyanide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,p-toluenesulfonylmethyl isocyanate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tosylmethylisocyanate Use and application,p-toluenesulfonylmethyl isocyanate technical grade,usp/ep/jp grade.


Related News: Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 1-(isocyanatomethylsulfonyl)-4-methylbenzene manufacturer Because API companies usually adopt a different synthetic route from the original research company, compared with the drug itself, the impurities contained in the generic drug API have not been verified by the original drug for many years of use and require more careful testing and control. 1-(isocyanatomethylsulfonyl)-4-methylbenzene supplier Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 1-(isocyanatomethylsulfonyl)-4-methylbenzene vendor Rigosertib, in its intravenous formulation, is currently in Phase 3 clinical development for the treatment of higher-risk MDS. 1-(isocyanatomethylsulfonyl)-4-methylbenzene factory Vietnam backtracked on Saturday and narrowed its restrictions to most flights from mainland China.